JP7049353B2 - 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 - Google Patents

糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 Download PDF

Info

Publication number
JP7049353B2
JP7049353B2 JP2019542722A JP2019542722A JP7049353B2 JP 7049353 B2 JP7049353 B2 JP 7049353B2 JP 2019542722 A JP2019542722 A JP 2019542722A JP 2019542722 A JP2019542722 A JP 2019542722A JP 7049353 B2 JP7049353 B2 JP 7049353B2
Authority
JP
Japan
Prior art keywords
group
alkyl
cycloalkyl
heterocyclyl
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506205A5 (enExample
JP2020506205A (ja
Inventor
マティアス エックハルト
ホルガー ワグナー
シュテファン ペーテルス
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020506205A publication Critical patent/JP2020506205A/ja
Publication of JP2020506205A5 publication Critical patent/JP2020506205A5/ja
Application granted granted Critical
Publication of JP7049353B2 publication Critical patent/JP7049353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019542722A 2017-02-08 2018-02-02 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 Active JP7049353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155191.4 2017-02-08
EP17155191 2017-02-08
PCT/EP2018/052620 WO2018146008A1 (en) 2017-02-08 2018-02-02 Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes

Publications (3)

Publication Number Publication Date
JP2020506205A JP2020506205A (ja) 2020-02-27
JP2020506205A5 JP2020506205A5 (enExample) 2021-01-14
JP7049353B2 true JP7049353B2 (ja) 2022-04-06

Family

ID=57995116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542722A Active JP7049353B2 (ja) 2017-02-08 2018-02-02 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物

Country Status (5)

Country Link
US (1) US10550127B1 (enExample)
EP (1) EP3580222B1 (enExample)
JP (1) JP7049353B2 (enExample)
CN (1) CN110300755B (enExample)
WO (1) WO2018146008A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7049349B2 (ja) 2017-01-26 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
US10919859B2 (en) 2017-01-26 2021-02-16 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7050792B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP2012529422A (ja) 2009-06-09 2012-11-22 武田薬品工業株式会社 新規な縮合環化合物およびその用途
JP2015511612A (ja) 2012-03-26 2015-04-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸誘導体およびｇｐｒ４０受容体作動薬としてのそれらの使用
US20160200734A1 (en) 2013-08-23 2016-07-14 Xinshan Kang Carboxylic acid compounds in treatment of diabetes mellitus
CN105820396A (zh) 2016-04-22 2016-08-03 宁波硫华聚合物有限公司 橡胶促进剂四硫化双五亚甲基秋兰姆预分散母胶粒及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2505322A (en) 1945-09-14 1950-04-25 Gibson Refrigerator Co Refrigerator cabinet
US2560111A (en) 1946-11-07 1951-07-10 Raymond T Levine Buffing chuck
US2656003A (en) 1948-02-27 1953-10-20 Inst Of Inventive Res High explosive disk-shaped charge for seismic exploration
US2727340A (en) 1953-08-31 1955-12-20 Alfred S Zanotta Portable tool for reconditioning crane rails
US5356287A (en) 1987-03-16 1994-10-18 Mcintyre Kevin M Simulating presence
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
US7664629B2 (en) 2005-07-19 2010-02-16 Xerox Corporation Second language writing advisor
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP2006271A4 (en) 2006-03-30 2011-08-10 Asahi Kasei Pharma Corp SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
ES2345916B1 (es) 2008-10-14 2011-09-14 Clipdorfix, S.L. Dispositivo de fijacion liberable de elementos adosados.
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
HK1210144A1 (en) * 2012-11-28 2016-04-15 勃林格殷格翰国际有限公司 New indanyloxydihydrobenzofuranylacetic acids
JP6283862B2 (ja) 2012-12-07 2018-02-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシジヒドロベンゾフラニル酢酸
AU2014221489B2 (en) 2013-02-28 2018-03-08 Tiumbio Co., Ltd. Tricyclic compound and use thereof
EP3074375B1 (en) * 2013-11-28 2018-04-04 Boehringer Ingelheim International GmbH New indanyloxyphenylcyclopropanecarboxylic acids
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
EP3347358B1 (en) * 2015-09-09 2019-11-27 Boehringer Ingelheim International GmbH [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP2012529422A (ja) 2009-06-09 2012-11-22 武田薬品工業株式会社 新規な縮合環化合物およびその用途
JP2015511612A (ja) 2012-03-26 2015-04-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸誘導体およびｇｐｒ４０受容体作動薬としてのそれらの使用
US20160200734A1 (en) 2013-08-23 2016-07-14 Xinshan Kang Carboxylic acid compounds in treatment of diabetes mellitus
CN105820396A (zh) 2016-04-22 2016-08-03 宁波硫华聚合物有限公司 橡胶促进剂四硫化双五亚甲基秋兰姆预分散母胶粒及其制备方法

Also Published As

Publication number Publication date
JP2020506205A (ja) 2020-02-27
EP3580222A1 (en) 2019-12-18
US20200017515A1 (en) 2020-01-16
CN110300755B (zh) 2022-10-04
CN110300755A (zh) 2019-10-01
EP3580222B1 (en) 2021-04-07
US10550127B1 (en) 2020-02-04
WO2018146008A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
CN110300755B (zh) 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物
JP7049349B2 (ja) ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7023969B2 (ja) ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP6968181B2 (ja) インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7050791B2 (ja) ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7050792B2 (ja) ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP6816107B2 (ja) インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
JP7050797B2 (ja) ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用
CN110312706B (zh) 茚满基氨基吡啶基环丙烷甲酸、其药物组合物及用途
EP3347358B1 (en) [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
BR102016018535A2 (pt) Ácidos indanilaminopiridilciclopropanocarboxílicos e composições farmacêuticas compreendendo os mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220325

R150 Certificate of patent or registration of utility model

Ref document number: 7049353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250